The abstract is read at the publisher; the summary is JClub's.
An eight-metabolite plasma panel predicts future bladder cancer risk in UK Biobank with AUC 0.98 in a held-out test and 0.92 in validation.
- Why it matters: Recurrence and lifelong surveillance in non–muscle-invasive bladder cancer leave a need to understand how metabolism changes before diagnosis and links to early tumor reprogramming.
- What they did: Baseline UK Biobank plasma metabolomics from 48,241 controls and 2,158 cases identified 64 metabolites linked to future risk, then targeted metabolomics and transcriptomics in 107 NMIBC patients and 56 controls supported an eight-metabolite model.
- The result: The panel also showed cross-biofluid performance in urine (AUC 0.75), and mechanistic work implicated butyrate in chromatin remodeling and AP-1–linked transcriptional programs tied to urothelial phenotypic plasticity.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.